Publications

November 23, 2023

Dr. Trier with Prof. Zeng, a renowned myopia researcher from China, at the EVER 2023 conference in València, Spain, October 26-28

At the EVER meeting in València, Spain, Dr. Klaus Trier was invited to talk at the myopia control session. Dr. Trier presented the latest analysis of data from 757 myopic children demonstrating high efficacy of 7-MX. For example, in children aged 7-10 and with less than 4 diopter myopia, the estimated effect of taking 2.5 of the current tablet per day is 1.71 diopter less myopia progression and 0.64 mm less eye elongation over six years.

In the ensuing debate, Dr. Trier stated that after several clinical trials have failed to show significant effect of low-concentration atropine eyedrops, 7-MX may be the only effective pharmaceutical for myopia control in current use.

The efficacy of optical devices designed to control myopia progression is insufficient, especially for children aged 7-10 years who are at risk of developing high myopia (more than 6 diopters), and it is therefore essential to develop an effective pharmaceutical myopia control treatment. 7-MX has been shown to be effective, safe and without side-effects and is therefore a good candidate.

April 05, 2023

TheiaLife signs Agreement with LifeSci Consulting for transaction advisory services for strategic partnering initiatives.

January 31, 2023

Featured in a second peer-reviewed publication in the International Journal of Ophthalmology. Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review”

August 18, 2022

Exciting news! Theialife is pleased to announce the first-in-class drug for Myopia control in Children – an unmet need. Please find the article released in the coveted British Journal of Ophthalmology.
Read more

Myopia, commonly known as nearsightedness, affects many children worldwide. It’s a condition where distant objects appear blurry while close-up objects remain clear. Genetics and lifestyle factors contribute to its development. To manage myopia, our novel drug 7-MX (a caffeine metabolite) has shown promise in reducing myopia progression in children. Our research has found that 7-MX is a safe and well-tolerated drug, and its potential to reduce myopia progression in children is very promising. As a novel drug, 7-MX’s antagonism of adenosine receptors and its potential to slow myopia progression make it an intriguing candidate for myopia control. This benefits young eyes and their long-term health.

Dry Eye Disease occurs when your eyes struggle to maintain a healthy tear film, an essential shield for keeping the eye's surface smooth, clear, and resistant to infections. Imbalances in tear production, quality, or distribution, can occur due to various factors, including physiological changes, environmental influence, or underlying medical conditions. These discrepancies lead to symptoms such as dryness and irritation, which can interfere with daily activities and overall comfort.

JOIN US

Building the future
of ophthalmology

We are on a mission to tackle some of the world's biggest health challenges, trying to find solutions where none exist. At Theialife, we seek partners who want to push back the boundaries of innovation on behalf of patients.

LET'S WORK TOGETHER